Provided by Tiger Trade Technology Pte. Ltd.

Alumis Inc.

24.17
+1.315.73%
Post-market: 23.83-0.3400-1.41%19:30 EDT
Volume:934.81K
Turnover:22.12M
Market Cap:3.12B
PE:-6.36
High:24.70
Open:22.98
Low:22.21
Close:22.86
52wk High:31.35
52wk Low:3.76
Shares:129.00M
Float Shares:109.67M
Volume Ratio:1.01
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8005
EPS(LYR):-2.8616
ROE:-93.65%
ROA:-45.34%
PB:6.90
PE(LYR):-8.45

Loading ...

Alumis price target raised to $39 from $38 at Morgan Stanley

TIPRANKS
·
May 15

Alumis Q1 Loss Narrows, Revenue Falls; Shares Down Pre-Bell

MT Newswires Live
·
May 15

HC Wainwright Downgrades Alumis to Neutral From Buy

MT Newswires Live
·
May 15

Alumis price target raised to $34 from $32 at Guggenheim

TIPRANKS
·
May 15

Alumis Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
May 15

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 15

Alumis Inc. (ALMS) Gets a Buy from Wells Fargo

TIPRANKS
·
May 15

Alumis Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 15

Alumis Q1 EPS $(0.74) Beats $(0.77) Estimate, Sales $1.741M Miss $2.767M Estimate

Benzinga Earnings
·
May 15

Alumis Q1 revenue drops, net loss narrows after trial completion

Reuters
·
May 15

Alumis Q1 FY26 net loss narrows 6% to $93.05 million; revenue drops 90% to $1.74 million

Reuters
·
May 15

Alumis posts corporate deck on next-generation TYK2 inhibitors for immune-mediated diseases

Reuters
·
May 15

BRIEF-Alumis Q1 Operating Expenses USD 100.15 Million

Reuters
·
May 15

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

THOMSON REUTERS
·
May 15

Why Is Alumis Stock Falling Monday?

Benzinga_recent_news
·
Mar 31

Alumis falls -16.1%

TIPRANKS
·
Mar 31

Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS

TIPRANKS
·
Mar 30

Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James

TIPRANKS
·
Mar 30

Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says

MT Newswires Live
·
Mar 30

Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating

MT Newswires Live
·
Mar 30